PAR-23-069: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $400,000 to small businesses. Applications closed on September 5, 2025.
From the official notice on Grants.gov, last changed January 4, 2023. Checked November 7, 2026.
- Award ceiling$400,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeSB1
- Clinical trialsNot allowed
- Funded byNINDS, NCCIH, NIAMS
- Median yearly award$399,912
- Typical project length2 years
Projects funded under PAR-23-069 were run by National Institute of Neurological Disorders and Stroke (NINDS, 4 projects), National Center for Complementary and Integrative Health (NCCIH, 1 project) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-069 in the NIH Guide.
Key dates
| Posted | January 3, 2023 |
|---|---|
| Deadline | September 5, 2025 |
| Archived by Grants.gov | October 11, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Funding Opportunity Announcement for additional details on eligibility.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $399,912; it allows up to $400,000 per award.
- Most of the money in the 5 programs behind this notice (77% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program. Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry.
Funded under PAR-23-069 so far
NIH funded 6 projects under PAR-23-069 in fiscal 2023 to 2026, at 6 institutions. The median yearly award was $399,912.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Embedded Entrepreneur to Commercialize Active Stimulation/Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care | Pascall Systems, Incorporated | 2026 | $199,806 |
| Commercialization of a Behavioral Digital Health Program for Individuals with Chronic Pain | 2MORROW, Inc | 2024 | $399,870 |
| Novel non-narcotic analgesic for acute and chronic pain | South Rampart Pharma, LLC | 2023 | $399,539 |
| Advancing precision pain medicines to the clinic | Navega Therapeutics, Inc. | 2023 | $400,000 |
| The Commercialization of High-Resolution, Spinal Cord Stimulation for Non-Opioid Treatment of Neuropathic Pain | Micro-Leads, Inc. | 2023 | $400,000 |
| Commercial Readiness in CTS Pain Management | Highland Instruments, Inc. | 2023 | $399,954 |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Who has won Vision Research grants before
From fiscal 2021 to 2025, Vision Research (93.867) awarded $3.4 billion across 3,275 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 137 | $139 million |
| The Leland Stanford Junior University | California | 87 | $96.5 million |
| The Regents of the University of California, San Francisco | California | 78 | $89.9 million |
| Duke University | North Carolina | 79 | $75.5 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 57 | $73.9 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Other programs behind this notice
- Arthritis, Musculoskeletal and Skin Diseases Research
- Research and Training in Complementary and Integrative Health
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-069 still open?
No. It closed on September 5, 2025.
Who can apply for HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)?
Closed September 5, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $400,000 each.
Who has been funded under PAR-23-069?
NIH RePORTER lists 6 projects funded under PAR-23-069 in fiscal 2023 to 2026, at 6 institutions. The most were at Pascall Systems, Incorporated, 2MORROW, Inc, South Rampart Pharma, LLC.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)